Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies

References

• McDermottDFAtkinsMBPD-1 as a potential target in cancer therapyCancer Med20132566267324403232
   PubMed Web of Science ®Google Scholar
• IshidaYAgataYShibaharaKHonjoTInduced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell deathEMBO J19921111388738951396582
   PubMed Web of Science ®Google Scholar
• BryanLJGordonLIBlocking tumor escape in hematologic malignancies: the anti-PD-1 strategyBlood Rev2015291253225260226
   PubMed Web of Science ®Google Scholar
• AgataYKawasakiANishimuraHExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInt Immunol1996857657728671665
   PubMed Web of Science ®Google Scholar
• ZhengPZhouZHuman cancer immunotherapy with PD-1/PD-L1 blockadeBiomark Cancer20157Suppl 2151826448693
   PubMedGoogle Scholar
• GhiottoMGauthierLSerriariNPD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1Int Immunol201022865166020587542
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• LiangSCLatchmanYEBuhlmannJERegulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responsesEur J Immunol200333102706271614515254
   PubMed Web of Science ®Google Scholar
• StanciuLABellettatoCMLaza-StancaVCoyleAJPapiAJohnstonSLExpression of programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulator ligand on human respiratory tract epithelial cells and regulation by respiratory syncytial virus and type 1 and 2 cytokinesJ Infect Dis2006193340441216388488
   PubMed Web of Science ®Google Scholar
• ZdrengheaMTJohnstonSLRole of PD-L1/PD-1 in the immune response to respiratory viral infectionsMicrobes Infect201214649549922285902
   PubMedGoogle Scholar
• LesterhuisWJSteerHLakeRAPD-L2 is predominantly expressed by Th2 cellsMol Immunol2011491–21322000002
   PubMed Web of Science ®Google Scholar
• YoungnakPKozonoYKozonoHDifferential binding properties of B7-H1 and B7-DC to programmed death-1Biochem Biophys Res Commun2003307367267712893276
   PubMed Web of Science ®Google Scholar
• FifeBTPaukenKEEagarTNInteractions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signalNat Immunol200910111185119219783989
   PubMed Web of Science ®Google Scholar
• KeirMELiangSCGuleriaITissue expression of PD-L1 mediates peripheral T cell toleranceJ Exp Med2006203488389516606670
   PubMed Web of Science ®Google Scholar
• LatchmanYELiangSCWuYPD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cellsProc Natl Acad Sci U S A200410129106911069615249675
   PubMed Web of Science ®Google Scholar
• YamazakiTAkibaHIwaiHExpression of programmed death 1 ligands by murine T cells and APCJ Immunol2002169105538554512421930
   PubMed Web of Science ®Google Scholar
• ShiLChenSYangLLiYThe role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignanciesJ Hematol Oncol2013617424283718
   PubMedGoogle Scholar
• BoniCFisicaroPValdattaCCharacterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infectionJ Virol20078184215422517287266
   PubMed Web of Science ®Google Scholar
• LiZLiNLiFImmune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinomaMedicine (Baltimore)20169552e574928033288
   PubMed Web of Science ®Google Scholar
• DayCLKaufmannDEKiepielaPPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionNature2006443710935035416921384
   PubMed Web of Science ®Google Scholar
• SehgalAWhitesideTLBoyiadzisMProgrammed death-1 checkpoint blockade in acute myeloid leukemiaExpert Opin Biol Ther20151581191120326036819
   PubMed Web of Science ®Google Scholar
• BrownJADorfmanDMMaFRBlockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine productionJ Immunol200317031257126612538684
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMIwasakiMProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerProc Natl Acad Sci U S A200710493360336517360651
   PubMed Web of Science ®Google Scholar
• NomiTShoMAkahoriTClinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancerClin Cancer Res20071372151215717404099
   PubMed Web of Science ®Google Scholar
• LesokhinAMAnsellSMArmandPNivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyJ Clin Oncol201634232698270427269947
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMMatsumuraNAbikoKBabaTKonishiIPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesInt J Clin Oncol201621346247326899259
   PubMed Web of Science ®Google Scholar
• BlankCBrownIPetersonACPD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cellsCancer Res20046431140114514871849
   PubMed Web of Science ®Google Scholar
• AhmadzadehMJohnsonLAHeemskerkBTumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood200911481537154419423728
   PubMed Web of Science ®Google Scholar
• LiJJieHBLeiYPD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironmentCancer Res201575350851825480946
   PubMed Web of Science ®Google Scholar
• BottaiGRaschioniCLosurdoAAn immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancersBreast Cancer Res201618112127912781
   PubMedGoogle Scholar
• ChaponMRandriamampitaCMaubecEProgressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytesJ Invest Dermatol201113161300130721346771
   PubMedGoogle Scholar
• MuenstSSoysalSDGaoFObermannECOertliDGillandersWEThe presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancerBreast Cancer Res Treat2013139366767623756627
   PubMed Web of Science ®Google Scholar
• WeiFZhongSMaZStrength of PD-1 signaling differentially affects T-cell effector functionsProc Natl Acad Sci U S A201311027E2480E248923610399
   PubMed Web of Science ®Google Scholar
• ZhangYHuangSGongDQinYShenQProgrammed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancerCell Mol Immunol20107538939520514052
   PubMed Web of Science ®Google Scholar
• Cimino-MathewsAThompsonETaubeJMPD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomasHum Pathol2016471526326527522
   PubMed Web of Science ®Google Scholar
• DongHStromeSESalomaoDRTumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasionNat Med20028879380012091876
   PubMed Web of Science ®Google Scholar
• BrusaDSerraSCosciaMThe PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemiaHaematologica201398695396323300177
   PubMed Web of Science ®Google Scholar
• YamamotoRNishikoriMKitawakiTPD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphomaBlood200811163220322418203952
   PubMed Web of Science ®Google Scholar
• IwaiYIshidaMTanakaYOkazakiTHonjoTMinatoNInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProc Natl Acad Sci U S A20029919122931229712218188
   PubMed Web of Science ®Google Scholar
• TelcianAGLaza-StancaVEdwardsMRRSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activityJ Infect Dis20112031859421148500
   PubMedGoogle Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• ZhangYWangLLiYProtein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinomaOnco Targets Ther2014756757324748806
   PubMed Web of Science ®Google Scholar
• GrossoJHCInzunzaDCardonaDMSimonJSGuptaAKSankarVAssociation of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumabJ Clin Oncol201331Suppl Abstract 3016
   Google Scholar
• MuenstSSchaerliARGaoFExpression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Res Treat20141461152424842267
   PubMed Web of Science ®Google Scholar
• ZengZShiFZhouLUpregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinomaPLoS One201169e2362121912640
   PubMed Web of Science ®Google Scholar
• DroeserRAHirtCViehlCTClinical impact of programmed cell death ligand 1 expression in colorectal cancerEur J Cancer20134992233224223478000
   PubMed Web of Science ®Google Scholar
• McDermottDFSosmanJASznolMAtezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and Immune Correlates From a Phase Ia StudyJ Clin Oncol201634883384226755520
   PubMed Web of Science ®Google Scholar
• BellmuntJMullaneSAWernerLAssociation of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinomaAnn Oncology2015264812817
   PubMed Web of Science ®Google Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• ArmandPImmune checkpoint blockade in hematologic malignanciesBlood2015125223393340025833961
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• RizviNAMazieresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol201516325726525704439
   PubMed Web of Science ®Google Scholar
• MotzerRJRiniBIMcDermottDFNivolumab for metastatic renal cell carcinoma: results of a randomized phase II trialJ Clin Oncol201533131430143725452452
   PubMed Web of Science ®Google Scholar
• CarbogninLPilottoSMilellaMDifferential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancersPLoS One2015106e013014226086854
   PubMed Web of Science ®Google Scholar
• BryanLJGordonLIReleasing the brake on the immune system: the PD-1 strategy for hematologic malignanciesOncology201529643143926091677
   PubMedGoogle Scholar
• MuenstSHoellerSDirnhoferSTzankovAIncreased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survivalHum Pathol200940121715172219695683
   PubMed Web of Science ®Google Scholar
• CarrerasJLopez-GuillermoARoncadorGHigh numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphomaJ Clin Oncol20092791470147619224853
   PubMed Web of Science ®Google Scholar
• TakahashiNIwasaSSasakiYSerum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancerJ Cancer Res Clin Oncol201614281727173827256004
   PubMed Web of Science ®Google Scholar
• FinkelmeierFCanliOTalAHigh levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosisEur J Cancer20165915215927039170
   PubMed Web of Science ®Google Scholar
• WahlinBEAggarwalMMontes-MorenoSA unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1 – positive, regulatory, cytotoxic, and helper T cells and macrophagesClin Cancer Res201016263765020068089
   PubMedGoogle Scholar
• HaHNamARBangJHSoluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapyOncotarget2016747766047661227780932
   PubMedGoogle Scholar
• BangYJChungHCShankaranVLBA-04Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012Ann Oncol201526Suppl 4iv118iv118
   Google Scholar
• TimmermanJHematologic cancers break down a ‘checkpoint’: targeting the PD-1/PD-L1 axisOncology (Williston Park)201529644044126091678
   PubMedGoogle Scholar
• GrzywnowiczMKarczmarczykASkorkaKExpression of programmed death 1 ligand in different compartments of chronic lymphocytic leukemiaActa Haematol2015134425526226159545
   PubMed Web of Science ®Google Scholar
• YuHShahsafaeiADorfmanDMGerminal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphomaAm J Clin Pathol20091311334119095563
   PubMedGoogle Scholar
• LaurentCCharmpiKGravellePSeveral immune escape patterns in non-Hodgkin’s lymphomasOncoimmunology201548e102653026405585
   PubMed Web of Science ®Google Scholar
• ChenBJChapuyBOuyangJPD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignanciesClin Cancer Res201319133462347323674495
   PubMed Web of Science ®Google Scholar
• YangHBueso-RamosCDiNardoCExpression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agentsLeukemia20142861280128824270737
   PubMed Web of Science ®Google Scholar
• KronigHKremmlerLHallerBInterferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatmentEur J Haematol201492319520324175978
   PubMed Web of Science ®Google Scholar
• NordeWJMaasFHoboWPD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantationCancer Res201171155111512221659460
   PubMed Web of Science ®Google Scholar
• ArmandPNaglerAWellerEADisabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialJ Clin Oncol201331334199420624127452
   PubMed Web of Science ®Google Scholar
• VranicSGhoshNKimbroughJPD-L1 Status in Refractory LymphomasPLoS One20161111e016626627861596
   PubMed Web of Science ®Google Scholar
• WilcoxRAFeldmanALWadaDAB7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersBlood2009114102149215819597183
   PubMed Web of Science ®Google Scholar
• AndorskyDJYamadaRESaidJPinkusGSBettingDJTimmermanJMProgrammed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cellsClin Cancer Res201117134232424421540239
   PubMed Web of Science ®Google Scholar
• MyklebustJHIrishJMBrodyJHigh PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cellsBlood201312181367137623297127
   PubMed Web of Science ®Google Scholar
• KiyasuJMiyoshiHHirataAExpression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphomaBlood2015126192193220126239088
   PubMed Web of Science ®Google Scholar
• KwonDKimSKimPJClinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomasHistopathology20166871079108926426431
   PubMed Web of Science ®Google Scholar
• GreenMRRodigSJuszczynskiPConstitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and post-transplant lymphoproliferative disorders: implications for targeted therapyClin Cancer Res20121861611161822271878
   PubMed Web of Science ®Google Scholar
• QuanLChenXLiuAPD-1 blockade can restore functions of T-cells in epstein-barr virus-positive diffuse large B-cell lymphoma In vitroPLoS One2015109e013647626361042
   PubMed Web of Science ®Google Scholar
• RosenwaldAWrightGLeroyKMolecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaJ Exp Med2003198685186212975453
   PubMed Web of Science ®Google Scholar
• GreenMRMontiSRodigSJIntegrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood2010116173268327720628145
   PubMed Web of Science ®Google Scholar
• BentzMBarthTFBruderleinSGain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell lineGenes Chromosomes Cancer200130439340111241792
   PubMed Web of Science ®Google Scholar
• ChapuyBRoemerMGStewartCTargetable genetic features of primary testicular and primary central nervous system lymphomasBlood2016127786988126702065
   PubMed Web of Science ®Google Scholar
• BiXWWangHZhangWWPD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer/T-cell lymphomaJ Hematol Oncol20169110927737703
   PubMedGoogle Scholar
• WangHWangLLiuWJHigh post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patientsOncotarget2016722330353304527105512
   PubMedGoogle Scholar
• KimWYJungHYNamSJExpression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosisVirchows Arch2016469558159027595782
   PubMed Web of Science ®Google Scholar
• KinosadaHYasunagaJIShimuraKHTLV-1 bZIP factor enhances T-Cell proliferation by impeding the suppressive signaling of co-inhibitory receptorsPLoS Pathog2017131e100612028046066
   PubMedGoogle Scholar
• ShimauchiTKabashimaKNakashimaDAugmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphomaInter J Cancer20071211225852590
   PubMed Web of Science ®Google Scholar
• KozakoTYoshimitsuMFujiwaraHPD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patientsLeukemia200923237538218830259
   PubMed Web of Science ®Google Scholar
• YasumaKYasunagaJTakemotoKHTLV-1 bZIP factor impairs anti-viral immunity by inducing co-inhibitory molecule, T cell immunoglobulin and ITIM domain (TIGIT)PLoS Pathog2016121e100537226735971
   PubMed Web of Science ®Google Scholar
• AnsellSMLesokhinAMBorrelloIPD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN Engl J Med2015372431131925482239
   PubMed Web of Science ®Google Scholar
• YounesAAndreas EngertASShippMargaretCheckmate 205: A Phase 2 Study of Nivolumab in Patients With Classical Hodgkin Lymphoma Following Autologous Stem Cell Transplantation and Brentuximab VedotinCopenhagen, DenmarkEHA212016
   Google Scholar
• TimmermanJMEngertAYounesACheckmate 205 update with minimum 12-Month Follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphomaBlood20161282211101110
   Web of Science ®Google Scholar
• HerishanuYKatzBZLipskyAWiestnerABiology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implicationsHematol Oncol Clin North Am201327217320623561469
   PubMed Web of Science ®Google Scholar
• RamsayADRodriguez-JustoMChronic lymphocytic leukaemia – the role of the microenvironment pathogenesis and therapyBr J Haematol20131621152423617880
   PubMedGoogle Scholar
• RossmannEDJeddi-TehraniMOsterborgAMellstedtHT-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL): an increased abnormal expression by advancing stageLeukemia200317112252225414576733
   PubMed Web of Science ®Google Scholar
• NunesCWongRMasonMFeganCManSPepperCExpansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progressionClin Cancer Res201218367868722190592
   PubMed Web of Science ®Google Scholar
• BatleviCLMatsukiEBrentjensRJYounesANovel immunotherapies in lymphoid malignanciesNat Rev Clin Oncol2016131254026525683
   PubMed Web of Science ®Google Scholar
• GribbenJTumor microenvironment: a rational therapeutic target for lymphomas EHA Learning CenterPresented at the 15th symposium of the EHAJune 14; 2015
   Google Scholar
• BergerRRotem-YehudarRSlamaGPhase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignanciesClin Cancer Res200814103044305118483370
   PubMed Web of Science ®Google Scholar
• GrzywnowiczMZaleskaJMertensDProgrammed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemiaPLoS One201274e3517822532845
   PubMed Web of Science ®Google Scholar
• RusakMEljaszewiczABolkunLPrognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemiaPol Arch Med Wewn20151257–855355926140546
   PubMed Web of Science ®Google Scholar
• RossilleDGressierMDamotteDHigh level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trialLeukemia201428122367237524732592
   PubMed Web of Science ®Google Scholar
• MuenstSHoellerSWilliNDirnhoferaSTzankovADiagnostic and prognostic utility of PD-1 in B cell lymphomasDis Markers2010291475320826917
   PubMed Web of Science ®Google Scholar
• WestinJRChuFZhangMSafety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialLancet Oncol2014151697724332512
   PubMed Web of Science ®Google Scholar
• YangZZGroteDMZiesmerSCXiuBNovakAJAnsellSMPD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survivalBlood Cancer J20155e28125700246
   PubMed Web of Science ®Google Scholar
• ChuFNeelapuSSAnti-PD-1 antibodies for the treatment of B-cell lymphoma: importance of PD-1+ T-cell subsetsOncoimmunology201431e2810124808975
   PubMedGoogle Scholar
• KantekureKYangYRaghunathPExpression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoidesAm J Dermatopathol201234112612822094231
   PubMed Web of Science ®Google Scholar
• KrishnanCWarnkeRAArberDANatkunamYPD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitisAm J Surg Pathol201034217818920087161
   PubMed Web of Science ®Google Scholar
• XerriLChetailleBSerriariNProgrammed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemiaHum Pathol20083971050105818479731
   PubMed Web of Science ®Google Scholar
• BladeJCibeiraMTFernandez de LarreaCRosinolLMultiple myelomaAnn Oncol201021Suppl 7vii313vii31920943635
   PubMedGoogle Scholar
• AtanackovicDLuetkensTKrogerNCoinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myelomaLeukemia2014285993100024153012
   PubMed Web of Science ®Google Scholar
• CastellaBFogliettaMSciancaleporePAnergic bone marrow Vgamma9Vdelta2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myelomaOncoimmunology2015411e104758026451323
   PubMed Web of Science ®Google Scholar
• HallettWHJingWDrobyskiWRJohnsonBDImmunosuppressive effects of multiple myeloma are overcome by PD-L1 blockadeBiol Blood Marrow Transplant20111781133114521536144
   PubMed Web of Science ®Google Scholar
• LiuJHamrouniAWolowiecDPlasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathwayBlood2007110129630417363736
   PubMed Web of Science ®Google Scholar
• YousefSMarvinJSteinbachMImmunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma- propagating pre-plasma cells in the bone marrow of multiple myeloma patientsBlood Cancer J20155e285
   PubMed Web of Science ®Google Scholar
• SponaasAMMoharramiNNFeyziEPDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapyPLoS One20151010e013986726444869
   PubMed Web of Science ®Google Scholar
• TamuraHIshibashiMYamashitaTMarrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myelomaLeukemia201327246447222828443
   PubMed Web of Science ®Google Scholar
• RosenblattJGlotzbeckerBMillsHPD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJ Immunother201134540941821577144
   PubMed Web of Science ®Google Scholar
• BensonDMJrBakanCEMishraAThe PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibodyBlood2010116132286229420460501
   PubMed Web of Science ®Google Scholar
• WangLWangHChenHSerum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myelomaOncotarget2015638412284123626515600
   PubMedGoogle Scholar
• GorgunGSamurMKCowensKBLenalidomide enhances immune checkpoint blockade-induced immune response in multiple myelomaClin Cancer Res201521204607461825979485
   PubMed Web of Science ®Google Scholar
• JingWGershanJAWeberJCombined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myelomaJ Immunother Cancer201531225614821
   PubMedGoogle Scholar
• KearlTJJingWGershanJAJohnsonBDProgrammed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myelomaJ Immunol2013190115620562823616570
   PubMed Web of Science ®Google Scholar
• AnsellSArmandPTimmermanJMNivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209–039)Blood201512623583583
   Google Scholar
• ArmandPShippMARibragVPembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b keynote-013 studyBlood20161282211081108
   Web of Science ®Google Scholar
• MoskowitzCHZinzaniPLFanaleMAPembrolizumab in relapsed/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 keynote-087 studyBlood20161282211071107
   Web of Science ®Google Scholar
• DingWLe-RademacherJCallTGPD-1 blockade with pembrolizumab in relapsed CLL including Richter’s transformation: an updated report from a phase 2 trial (MC1485)Blood20161282243924392
   Google Scholar
• JainNBasuSThompsonPANivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trialBlood2016128225959
   Web of Science ®Google Scholar
• ZinzaniPLRibragVMoskowitzCHPhase 1b Study of Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma: results from the ongoing keynote- 013tTrialBlood201612822619619
   Google Scholar
• BadrosAZHyjekEMaNPembrolizumab in combination with pomalidomide and dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)Blood201612822490490
   Google Scholar
• San MiguelJMateosM-VShahJJPembrolizumab in combination with lenalidomide and low-dose dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): keynote-023Blood201512623505505
   Google Scholar